Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: This study aimed to describe the health-related quality of life (HRQoL) outcomes for Korean chronic hepatitis C patients and to investigate the impact of patient and virus-related factors on HRQoL. Methods: HRQoL was assessed in 235 hepatitis C virus (HCV)-infected patients from seven nationwide tertiary hospital, including those with liver cirrhosis and hepatocellular carcinoma (HCC), using the Shor-Form 36 (SF-36) version 2 and the European quality of life questionnaire-5 dimensions (EQ-5D-3L). Results: The SF-36 physical (48.8±8.3) and mental (46.2±11.7) component summary scores of the HCV-infected patients were below normal limits. Of the eight domains, general health, vitality, and mental health tended to show low scores. Patients with decompensated cirrhosis had the lowest HRQoL, while HCC and chronic hepatitis patients had similar HRQoL results. The EQ-5D index was low (0.848±0.145) in the HCV infected patients. Multivariable analysis showed age ≤65 years, high monthly family income (>$2,641), low comorbidity score, and sustained virologic response (SVR) were independently associated with favorable HRQoL. Conclusions: HRQoL in Korean patients with chronic HCV infection was low and was affected by cirrhosis severity, SVR, and comorbidity as well as income, which had the strongest effect. Therefore, HRQoL may be improved by antiviral therapy with reasonable costs to prevent cirrhosis progression.
Abstract
Background/Aims: This study aimed to describe the health-related quality of life (HRQoL) outcomes for Korean chronic hepatitis C patients and to investigate the impact of patient and virus-related factors on HRQoL. Methods: HRQoL was assessed in 235 hepatitis C virus (HCV)-infected patients from seven nationwide tertiary hospital, including those with liver cirrhosis and hepatocellular carcinoma (HCC), using the Shor-Form 36 (SF-36) version 2 and the European quality of life questionnaire-5 dimensions (EQ-5D-3L). Results: The SF-36 physical (48.8±8.3) and mental (46.2±11.7) component summary scores of the HCV-infected patients were below normal limits. Of the eight domains, general health, vitality, and mental health tended to show low scores. Patients with decompensated cirrhosis had the lowest HRQoL, while HCC and chronic hepatitis patients had similar HRQoL results. The EQ-5D index was low (0.848±0.145) in the HCV infected patients. Multivariable analysis showed age ≤65 years, high monthly family income (>$2,641), low comorbidity score, and sustained virologic response (SVR) were independently associated with favorable HRQoL. Conclusions: HRQoL in Korean patients with chronic HCV infection was low and was affected by cirrhosis severity, SVR, and comorbidity as well as income, which had the strongest effect. Therefore, HRQoL may be improved by antiviral therapy with reasonable costs to prevent cirrhosis progression.
참고문헌 (28)
- Jeffrey D Stanaway, "The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013", The Lancet, 388(10049), pp.1081~1088 (2016), Elsevier BV[DOI]
- Gane E, "Strategies to manage hepatitis C virus (HCV) infection disease burden-volume 2", J Viral Hepat, 22(Suppl 1), pp.46~73 (2015)
- David Whiteley, "Health-Related Quality of Life for individuals with hepatitis C: A narrative review", International Journal of Drug Policy, 26(10), pp.936~949 (2015), Elsevier BV[DOI]
- Measuring healthy days: population assessment of health-related quality of life, "Centers for Disease Control and Prevention", Centers for Disease Control and Prevention, ~ (2000)
- Brennan M.R. Spiegel, "Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment", Hepatology, 41(4), pp.790~800 (2005), Wiley[DOI]
- Peter Jepsen, "Comorbidity and survival of Danish cirrhosis patients: A nationwide population-based cohort study", Hepatology, 48(1), pp.214~220 (2008), Wiley[DOI]
- Ki Tae Suk, "Revision and update on clinical practice guideline for liver cirrhosis", The Korean Journal of Hepatology, 18(1), pp.1~ (2012), The Korean Association for the Study of the Liver[DOI]
- Jeong Min Lee, "2014 KLCSG-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma: HCC Diagnostic Algorithm", Digestive Diseases, 32(6), pp.764~777 (2014), S. Karger AG[DOI]
- Chang-Wan Han, "Development of the Korean Version of Short-Form 36-Item Health Survey: Health Related QOL of Healthy Elderly People and Elderly Patients in Korea", The Tohoku Journal of Experimental Medicine, 203(3), pp.189~194 (2004), Tohoku University Medical Press[DOI]
- Seon Ha Kim, "Psychometric Properties of the Korean Short Form-36 Health Survey Version 2 for Assessing the General Population", Asian Nursing Research, 7(2), pp.61~66 (2013), 한국간호과학회
- Richard Norman, "International Comparisons in Valuing EQ-5D Health States: A Review and Analysis", Value in Health, 12(8), pp.1194~1200 (2009), Elsevier BV[DOI]
- Yeon-Kyeng Lee, "South Korean Time Trade-Off Values for EQ-5D Health States: Modeling with Observed Values for 101 Health States", Value in Health, 12(8), pp.1187~1193 (2009), Elsevier BV[DOI]
- Ock M, "Measuring Health Related Quality of Life Using EQ-5D in South Korea", J Health Tech Assess, 1, pp.103~ (2013)
- Gralnek IM, "Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease: the LDQOL 1.0", Am J Gastroenterol, 95, pp.3552~3565 (2000)
- Marilyn Bergner, "The Sickness Impact Profile: Development and Final Revision of a Health Status Measure", Medical Care, 19(8), pp.787~805 (1981), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Simone M van der Plas, "Generic and disease-specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional study", BMC Gastroenterology, 3(1) (2003), Springer Nature[DOI]
- James G. Orr, "Health related quality of life in people with advanced chronic liver disease", Journal of Hepatology, 61(5), pp.1158~1165 (2014), Elsevier BV[DOI]
- Seon-Ha Kim, "Deriving a mapping algorithm for converting SF-36 scores to EQ-5D utility score in a Korean population", Health and Quality of Life Outcomes, 12(1) (2014), Springer Nature[DOI]
- Szende A, "Self-reported population health: an international perspective based on EQ-5D" (2014), Springer
- H. L. Tillmann, "Quality of life in patients with various liver diseases", Journal of Viral Hepatitis, 18(4), pp.252~261 (2011), Wiley[DOI]
- Sang Soo Lee, "Treatment rate and factors related to interferon-based treatment initiation for chronic hepatitis C in South Korea", Journal of Medical Virology, 88(2), pp.275~281 (2016), Wiley[DOI]
- 박창근, "만성 바이러스성 간질환 환자의 삶의 질 평가 및 관련인자 분석", Clinical and Molecular Hepatology, 9(2003), pp.212~221 (2003), 대한간학회
- J. S. Bajaj, "PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis", Alimentary Pharmacology & Therapeutics, 34(9), pp.1123~1132 (2011), Wiley[DOI]
- Sinakos E, "Health-related quality of life in Greek chronic hepatitis C patients during pegylated interferon and ribavirin treatment", Hippokratia, 14, pp.122~125 (2010)
- Ava A John-Baptiste, "Sustained Responders Have Better Quality of Life and Productivity Compared With Treatment Failures Long After Antiviral Therapy for Hepatitis C", The American Journal of Gastroenterology, 104(10), pp.2439~2448 (2009), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Donna M Evon, "Prospective Analysis of Depression During Peginterferon and Ribavirin Therapy of Chronic Hepatitis C: Results of the Virahep-C Study", The American Journal of Gastroenterology, 104(12), pp.2949~2958 (2009), Ovid Technologies (Wolters Kluwer Health)[DOI]
- N. H. Nguyen, "Response to pegylated interferon and ribavirin in Asian American patients with Chronic hepatitis C genotypes 1 vs 2", 3 vs 6, 2010, pp.17(10), 691~697[DOI]
- Zobair M. Younossi, "Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir", Medicine, 95(9), pp.e2702~ (2016), Ovid Technologies (Wolters Kluwer Health)[DOI]